Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Myasthenia Gravis Clinical Trial

Official title:

A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06106672
• Other study ID #: CNP-106-5.001
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: May 31, 2024
• Est. completion date: August 2026

Study information

• Verified date: May 2024
• Source: COUR Pharmaceutical Development Company, Inc.
• Contact: Jason Penix
• Phone: 773-339-5745
• Email: jpenix[@]courpharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.

Description:

This is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106. The clinical study lasts 222-days (up to 42 days for Screening, 180 Study Days). Subjects ages 18-75 with generalized myasthenia gravis (MG) will be screened up to 42 days prior to enrollment into the clinical study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 54
• Est. completion date: August 2026
• Est. primary completion date: June 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.

2. Men and non-pregnant women, ages 18-75 years inclusive.

3. Female subjects of childbearing potential must agree not to become pregnant during the clinical study, have a negative pregnancy test at the Screening Visit, and agree to

one of the following:

• Use two highly effective forms of birth control starting at initial screening and continuing throughout the study duration.
• Practice abstinence starting at initial screening and continuing throughout the study duration.

4. Subjects with a Myasthenia Gravis Foundation of America Clinical Classification Class III-IV (Cohort 1). Upon successful DMC review and approval of preliminary safety data obtained from Cohort 1 through Day 15, Cohort 2 will enroll subjects with MGFA Clinical Classification Class II-IV.

5. Subjects positive for anti-AChR antibodies by radioimmunoassay (RIA) (Mayo Clinic). 6, Subjects with MG-ADL Score = 6 at Screening and Baseline Visit with = 50% of the score derived from non-ocular symptoms.

7. Subjects with QMG Score = 11 at Screening and Baseline Visit. 8. For subjects on any medication used to treat the symptoms of MG (ex. Corticosteroids, pyridostigmine), subjects must be on a stable dose for a minimum of 90 days prior to enrollment and must agree not to increase their dose through clinical study duration unless reviewed and approved by the medical monitor and the site investigator.

9. Female subjects who agree to not breastfeed starting at initial screening and throughout the study duration.

10. Female subjects who agree to not donate ova starting at initial screening and throughout the study duration.

11. Male subjects with a spouse or partner of childbearing potential, who themselves and their spouse or partner agree to practice an effective form of birth control as discussed with the study doctor or study staff starting at Screening and throughout the study duration.

Exclusion Criteria:

1. Subjects with a Myasthenia Gravis Foundation of America Clinical Classification Class I or V.

2. Subjects with a history of cerebrovascular accident in the past 12 months.

3. Subjects with MG-ADL Score < 6 at Screen or Subjects with MG-ADL Score = 6 at Screen with ? 50% of the score derived from non-ocular symptoms.

4. Subjects with QMG Score < 11 at Screen.

5. Subjects who have used the following medications:

• Tacrolimus within 6 months prior to the first dosing;
• Methotrexate within 5 half-lives or 90 days after last dose (whichever is longer);
• Anti-FcRn inhibitors (ex. Efgartigimod) within 5 half-lives or 90 days after last dose (whichever is longer);
• C5 complement inhibitor (ex. Eculizumab) within 5 half-lives or 90 days after last dose (whichever is longer);
• Anti-CD20 (ex. Rituximab) within 5 half-lives for 90 days after last dose (whichever is longer);
• Inclusion of subjects on other immunomodulatory drugs will be at the discretion of the medical monitor and study site investigator.

6. Subjects who have used immunoglobulins given SC or IV (SCIg or IVIg) or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.

7. Subjects who have had thymectomy or any other thymic surgery performed within 12 months prior to Screening.

8. Subjects with untreated thymic malignancy, carcinoma, or thymoma.

9. Subjects with a history of tuberculosis or positive PPD skin test.

10. Subjects who have received administration of any live vaccine (other than intranasal Influenza) within 28 days or subunit vaccine within 14 days prior to Screening or are planning to receive any vaccination throughout the study duration.

11. Subjects who have received any COVID-19 vaccine within 14 days prior to Screening. Subjects who have received the first dose of any COVID-19 vaccine may not screen for the study until 14 days following their last dose of the vaccine if applicable.

12. Subjects with laboratory test results at Screening or prior to study dosing that are outside the normal limits and considered by the investigator to be clinically significant. Note: Clinically significant laboratory test results at screening that are related to the condition (MG) are acceptable as long as all inclusion and no other exclusion criteria are met.

13. Subjects with positive test results for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody as determined at Screening.

14. Subjects with a history of or currently active immune disorders other than MG (including autoimmune disease) unless the condition, after discussion with the medical monitor and study site investigator, has been deemed to be acceptable for the subject's participation in this clinical study.

15. Subjects with a history of or current active diseases other than myasthenia gravis requiring immunosuppressive drugs (including azathioprine, prednisone, prednisolone, budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unless the condition, after discussion with the medical monitor and site investigator, has been deemed to be acceptable for the subject's participation in this clinical study.

16. Subjects with a clinical history of significant cardiovascular disease as determined by the Investigator.

17. Subjects with a complication or medical history of malignancy within the past 5 years which, in the investigator's opinion, makes the subject unsuitable for study participation.

18. Subjects with a history of mast cell activation disease.

19. Subjects who, in the investigator's opinion, will be unable to adhere to study procedures.

20. Subjects who have received an investigational therapy other than CNP-106 within 28 days or 5 half-lives, whichever is longer, prior to Screening.

21. Subjects with any known active condition which, in the investigator's opinion, makes the subject unsuitable for study participation.

22. Known sensitivity to any components of CNP-106 (PLGA, sucrose, mannitol or sodium citrate).

Related Conditions & MeSH terms

• Muscle Weakness
• Myasthenia Gravis

Intervention

Drug:
• CNP-106
CNP-106 is comprised of an antigenic AChR Peptide Pool (~1 µg of each AChRa and AChRe peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).

Other:
• Placebo
CNP-106 Placebo

Locations

Country	Name	City	State
United States	Infusion for Health	Brea	California
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Ohio State University Wexner Medical Center	Columbus	Ohio
United States	Nerve and Muscle Center of Texas	Houston	Texas
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	Quantix Research, LLC	Miami	Florida
United States	University of Minnesota	Minneapolis	Minnesota
United States	Yale University	New Haven	Connecticut
United States	University of California, Irvine	Orange	California
United States	Barrow Neurological Institute	Phoenix	Arizona
United States	Neuromuscular Clinic and Research Center	Phoenix	Arizona
United States	Virginia Commonwealth University	Richmond	Virginia
United States	University of South Florida	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
COUR Pharmaceutical Development Company, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs),	Frequency tables will be presented by treatment group for all AEs and SAEs by System Organ Class (SOC) and Preferred Term (PT). Frequency tables will also be produced by treatment group for AEs leading to COUR Pharmaceuticals Development Company, Inc. Confidential CNP-106-5.001 Protocol; IND 28774 Page 53 of 65 discontinuation from IP and study, by severity, and by causality. No formal statistical testing will be done.	Through study day 180
Secondary	Change from baseline in antigen specific CD4+ and CD8+ T cell levels in PBMC at Day 60, 90, and 180.	The mean change from Baseline to the endpoint within CNP-106 and Placebo treatment groups will be analyzed using ANOVA.	Through study day 180
Secondary	Change from baseline in activated antigen specific CD4+ and CD8+ T cell levels in PBMC at Day 60, 90, and 180.	The mean change from Baseline to the endpoint within CNP-106 and Placebo treatment groups will be analyzed using ANOVA.	Through study day 180